** Shares of drug developer Acelyrin Inc SLRN.O fall 16.5% to $3.38 after the bell
** SLRN says its experimental drug zokibep failed to meet the main goal of a mid-to-late stage study for patients with uveitis, a type of eye inflammation
** Adds co will not make any additional internal investment in developing izokibep
** Will focus on developing its other drug lonigutamab for thyroid eye disease
** Separately, CFO Gil Labrucherie has notified co of his intention to resign, effective Jan. 2, 2025, to pursue an external opportunity, filing shows
** Up to last close, stock down ~45% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
Comments